Application of targeted radiotherapy/gene therapy to bladder cancer cell lines.

OBJECTIVES A targeted radiotherapy/gene therapy strategy for transitional cell carcinoma of bladder is described, using [131I]meta-iodobenzylguanidine ([131I]MIBG), a radionuclide combined with a tumour-seeking drug. The aim is to decrease side effects from radiation toxicity, while increasing radiation dose to tumour. This tumour cell kill approach is augmented by radiological bystander effects. METHODS The bladder cancer cell line EJ138 was transfected with a gene encoding the noradrenaline transporter (NAT) under the control of tumour-specific telomerase promoters. Resulting uptake of [131I]MIBG was assessed by gamma-counting of cell lysates, and NAT transgene expression by real-time RT-PCR. Cell kill of monolayers and disaggregated spheroids, dosed with [131I]MIBG, was assessed by clonogenic assay. RESULTS NAT gene transfected cells exhibited a significantly increased active uptake of [131I]MIBG, leading to dose-dependent cell kill. Clonogenic assay of disaggregated spheroids, a three-dimensional model, suggested cell kill via bystander effects. CONCLUSIONS Expression of a functional NAT after in vitro transfection of bladder cancer cells with the NAT gene under the control of telomerase promoters leads to active uptake of [131I]MIBG and dose-dependent cell kill. This strategy could produce a promising new treatment option for bladder cancer.

[1]  Nam W. Kim,et al.  Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP) , 1997, Nucleic Acids Res..

[2]  M. Lykourinas,et al.  Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. , 2003, Urology.

[3]  S. Eissa,et al.  Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer. , 2003, European urology.

[4]  S. Gelmini,et al.  Telomerase in urological malignancy. , 2001, The Journal of urology.

[5]  S. Kyo,et al.  Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  S. Kyo,et al.  Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  S. Goodison,et al.  Role of telomerase in cell senescence and oncogenesis. , 2000, Annual review of medicine.

[8]  M. Boyd,et al.  Targeting Radiotherapy to Cancer by Gene Transfer , 2003, Journal of biomedicine & biotechnology.

[9]  B. Liu,et al.  Telomerase in human bladder cancer. , 2000, The Urologic clinics of North America.

[10]  W. See,et al.  Evaluation of gene transfer efficiency by viral vectors to murine bladder epithelium. , 2001, The Journal of urology.

[11]  P. Carroll,et al.  The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. , 1995, International journal of radiation oncology, biology, physics.

[12]  T. Shimada,et al.  Preferential gene transfer to BBN-induced rat bladder tumor by simple instillation of adenoviral vector. , 2001, Urology.

[13]  A. Hochberg,et al.  Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  E. Parkinson,et al.  Cloning and characterization of human and mouse telomerase RNA gene promoter sequences , 1998, Oncogene.

[15]  T. Wheldon,et al.  Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine , 1999, Gene Therapy.

[16]  M. Gaze,et al.  Radiolabelled mIBG in the treatment of neuroblastoma. , 1996, European journal of cancer.

[17]  T. Koyanagi,et al.  An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies , 2000, Cancer Gene Therapy.

[18]  S. Cohen,et al.  Epidemiology and etiology of bladder cancer. , 1992, Seminars in surgical oncology.

[19]  Yanhong Zhang,et al.  Enhanced suicide gene therapy by chimeric tumor‐specific promoter based on HSF1 transcriptional regulation , 2003, FEBS letters.

[20]  K. Koeneman,et al.  A novel tumor-specific gene therapy for bladder cancer. , 1999, Medical hypotheses.

[21]  T. Wheldon,et al.  A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma. , 2000, Medical and pediatric oncology.

[22]  A. Barrett,et al.  The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  R. Glasspool,et al.  Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954 , 2001, Oncogene.

[24]  B. Fang,et al.  Telomerase promoter-driven cancer gene therapy. , 2003 .

[25]  M. Zalutsky,et al.  An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation‐mediated bystander effects , 2004, The journal of gene medicine.

[26]  M. Schuler,et al.  Successful Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients With Bladder Cancer by Intravesical Vector Instillation , 2002 .

[27]  B. Djordjevic.  Bystander effects: a concept in need of clarification. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[28]  R. Glasspool,et al.  Telomerase and cancer: time to move from a promising target to a clinical reality , 2001, The Journal of pathology.

[29]  T. Wheldon,et al.  A gene therapy/targeted radiotherapy strategy for radiation cell kill by [131I]meta‐iodobenzylguanidine , 2001, The journal of gene medicine.

[30]  J. Shay,et al.  A survey of telomerase activity in human cancer. , 1997, European journal of cancer.

[31]  S. Sukumar,et al.  Applications of telomerase research in the fight against cancer. , 1999, Molecular medicine today.

[32]  T. Fujioka,et al.  Expression of the catalytic subunit associated with telomerase gene in human urinary bladder cancer. , 1999, The Journal of urology.

[33]  H. von der Maase,et al.  Radiotherapy in bladder cancer. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  F. Guillemin,et al.  A new method of implanting orthotopic rat bladder tumor for experimental therapies , 2002, International journal of cancer.

[35]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[36]  K M Prise,et al.  Direct evidence for a bystander effect of ionizing radiation in primary human fibroblasts , 2001, British Journal of Cancer.

[37]  Markus Müller.  Telomerase: Its clinical relevance in the diagnosis of bladder cancer , 2002, Oncogene.

[38]  H. Caron,et al.  Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  C. Harley.  Telomerase is not an oncogene , 2002, Oncogene.

[40]  E. Hall,et al.  The bystander effect. , 2003, Health physics.

[41]  W. Keith,et al.  Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill , 2001, Oncogene.

[42]  V. Rufini,et al.  131I-MIBG therapy of neural crest tumours (review). , 1997, Anticancer research.

[43]  A. Barrett,et al.  131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. , 1992, British Journal of Cancer.

[44]  M. Boyd,et al.  Transfectant mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy , 2002, The journal of gene medicine.

[45]  K E Britton,et al.  Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I‐meta‐iodobenzylguanidine (131I‐mIBG) , 2001, Clinical endocrinology.

[46]  D. Swinkels,et al.  Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas , 2000, International journal of cancer.